On May 26, 2022, RELIEF THERAPEUTICS announced that the parent company, NRx Pharmaceuticals, of its collaboration partner with respect to aviptadil, announced results of a review conducted by the Data Safety and Monitoring Board.

The Independent DSMB overseeing the ACTIV-3b (TESICO) study determined that evaluation of aviptadil should cease due to futility.